Rethinking B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide in hemodialysis patients

Rethinking B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide in hemodialysis patients - Rethinking of natriuretic peptides in h0emodialysis patients

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000061311

Enrollment

168

Registered

2026-04-19

Start date

2025-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

168 patients undergoing maintenance hemodialysis, 75 had not received sacubitril/valsartan, while 93 had been receiving the same medication for at least 3 months.

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: A patient undergoing maintenance hemodialysis three times a week at Fujita Memorial Hospital.

Exclusion criteria

Exclusion criteria: Patients who have been taking sacubitril/valsartan for less than 3 months.

Design outcomes

Primary

Measure	Time frame
1.To examine whether a positive correlation between BNP and NT-proBNP is observed according to the presence or absence of sacubitril/valsartan therapy, and whether a similar correlation is maintained irrespective of its administration. 2.To determine, based on changes in BNP and NT-proBNP before and after hemodialysis, whether measurements in hemodialysis patients should be interpreted using pre-dialysis or post-dialysis values.	—

Measure

Time frame

1.To examine whether a positive correlation between BNP and NT-proBNP is observed according to the presence or absence of sacubitril/valsartan therapy, and whether a similar correlation is maintained irrespective of its administration. 2.To determine, based on changes in BNP and NT-proBNP before and after hemodialysis, whether measurements in hemodialysis patients should be interpreted using pre-dialysis or post-dialysis values.

—

Countries

Japan

Contacts

Public ContactRYOICHI MIYAZAKI

Fujita Memorial Hospital Iternal Medicine

ryoichi@mitene.or.jp0776211277

Outcome results